SYL040012, Treatment for Open Angle Glaucoma

Inclusion Criteria: * Patients older than 18 years of either sex * Good or fair general health as assessed by the investigator. * Signed informed consent prior to any clinical trial-related procedures * Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT) * Post-washout mean IOP above target range * BCVA 1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200) * Stable visual field * Central corneal thickness 480-620 μm * Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes Exclusion Criteria: * Pregnant or breastfeeding females * Females of childbearing potential not willing to use a medically acceptable contraceptive method * Clinically significant systemic disease * Changes of systemic medication that could have a substantial effect on IOP * Known hypersensitivity to any component of the formulations * Unable to comply with the clinical trial requirements * Clinically significant abnormalities in laboratory tests * Severe visual field defect * Any secondary glaucoma * Pseudoexfoliation or pigment dispersion component, history of angle closure or narrow angles. * IOP ≥ 35 mm Hg in any eye * Previous non-laser glaucoma surgery or glaucoma laser procedures (e.g., laser trabeculoplasty) and refractive surgery * Any ocular surgery or laser treatment, cataract extraction or ocular trauma within 6 months prior to Baseline * Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at baseline (Visit 0), or a history of herpes simplex keratitis * Clinically significant ocular disease